Regulatory T cells: gatekeepers of immunological tolerance {#FPar1}
==========================================================

Over the past 20 years it has been established that specific populations of T cells exist and that their primary function is the suppression or regulation of the immune response \[[@CR1]\]. Given the generic term 'regulatory T cells' (Tregs), these cells form a key part of peripheral immune regulation. A lack of Treg-mediated control has been shown to play a role in numerous autoimmune disorders \[[@CR2]\] and in tumour immunology Tregs have been implicated as a mechanism by which tumours evade immune recognition \[[@CR3]\].

Regulatory function has been ascribed to a wide variety of different T cell subpopulations, with sometimes confusing nomenclature. In this review, we will adopt recent recommendations and discuss two different populations of CD4^+^ Tregs, delineated based on constitutive expression of the transcription factor forkhead box P3 (FOXP3). More details on Treg nomenclature, generation and function are shown in the Text box.

CD4^+^FOXP3^+^ Tregs {#Sec1}
====================

Perhaps the clearest evidence for a vital role in preventing autoimmunity has been found for a population of CD4^+^ T cells defined by constitutive expression of high levels of CD25 (the IL-2 receptor α chain) and expression of the transcription factor FOXP3. FOXP3^+^ Tregs can either be generated in the thymus (tTregs, previously known as naturally occurring Tregs \[nTregs\]) or periphery (pTregs, previously called adaptive Tregs \[aTregs\]) \[[@CR1], [@CR4]\]. However, because there are currently no definitive phenotypic markers that can be used to differentiate between these cell types in humans, we will use here the generic term 'FOXP3^+^ Treg' to refer to both tTreg and pTreg subtypes. Generation of FOXP3^+^ Tregs depends on the encounter with antigen and signalling via IL-2 \[[@CR4]\], a cytokine vital not only for the generation of these cells but also for their survival, expansion and function in the periphery \[[@CR5], [@CR6]\]. FOXP3^+^ Tregs exert their suppressive capabilities via several cell-to-cell-contact-dependent and -contact-independent mechanisms. Due to high levels of CD25 expression, FOXP3^+^ Tregs can act as an 'IL-2 sink', depriving pathogenic T cells of this growth factor \[[@CR7]\]. Suppression can also occur by secretion of suppressive soluble factors, such as TGF-β, IL-10, IL-35 and adenosine, as well as expression of molecules such as lymphocyte-activation gene 3 (LAG-3), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granzyme B \[[@CR8]\]. The clearest link between FOXP3^+^ Tregs and autoimmunity comes from the disorder immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX), in which there are loss-of-function mutations in the *FOXP3* gene \[[@CR9]\]. Affected individuals develop a wide range of immunopathology and autoimmune disorders, including type 1 diabetes in \>80% of individuals before the age of 2 years. This demonstrates that, if profound, defects in FOXP3^+^ Tregs can elicit type 1 diabetes in most individuals regardless of other genetic or environmental influences, thus pointing to a key role for these cells in maintaining islet-specific tolerance. Similarly, scurfy mice, lacking a functional *Foxp3* gene, display a profoundly dysregulated immune system, including severe generalised autoimmunity, and die of uncontrolled lymphoproliferative disease \[[@CR10]\]. Conversely, therapies that increase the number or functional capacity of FOXP3^+^ Tregs can lead to prevention or cure of disease in preclinical models of autoimmunity, including type 1 diabetes \[[@CR11]\].

Defective FOXP3^+^ Treg function: a key immunophenotype in type 1 diabetes {#Sec2}
==========================================================================

The importance of understanding whether type 1 diabetes is caused by defective immune regulation is clear: not only could it clarify aspects of type 1 diabetes pathogenesis but it could also identify and lead to the development of novel therapeutic interventions or adoptive transfer strategies that specifically strengthen regulatory pathways and, thereby, delay or prevent disease onset in at-risk individuals. Although the defects are not as profound as those seen in individuals affected by IPEX, there is mounting evidence that individuals with polygenic type 1 diabetes display alterations in the fitness and function of FOXP3^+^ Tregs. The theory that such alteration may contribute to disease pathogenesis is supported by the observation that many of the type 1 diabetes susceptibility loci identified by genome-wide association studies may well influence Treg function (e.g. *IL2RA*, *IL2*, *PTPN2*, *CTLA4* and *IL10*) \[[@CR12]\], a theme that is discussed in more detail below.

One early report suggested that FOXP3^+^ Tregs (defined as CD4^+^CD25^+^ T cells) were decreased in frequency in individuals with type 1 diabetes (vs control individuals without diabetes) \[[@CR13]\]. However, the use of more accurate markers to define these Tregs, including low expression of CD127 and expression of FOXP3, has led to a consensus that the overall frequency of FOXP3^+^ Tregs is unaltered in individuals with type 1 diabetes \[[@CR14]--[@CR17]\]. It is worth noting that these markers are not perfect and that in humans, for example, FOXP3 is transiently upregulated on recently activated effector T cells (Teff), meaning that cells identified by this phenotype are likely to contain a mixture of Tregs and non-regulatory cells \[[@CR18]\]. More recently, the selective demethylation of certain regions of the FOXP3 locus (the Treg-specific demethylated region \[TSDR\]) has been used to identify stable, functionally competent Tregs, allowing their discrimination from activated CD4^+^CD25^+^FOXP3^+^ Teffs \[[@CR19]--[@CR21]\]. However, to date, no difference in the frequency of FOXP3^+^ Tregs has been reported using this or any other enumeration method. Recently, it has also become clear that FOXP3^+^ Tregs are not simply a population of cells sharing a common phenotype but are in fact a heterogeneous mixture of cellular phenotypic subtypes that reflect different states of maturation, differentiation and activation, or use different methods or targets of suppression \[[@CR22], [@CR23]\]. It is therefore possible that a shift in the balance or alteration in the frequency of a subtype of Tregs might be present in type 1 diabetes. Indeed Okubo et al recently demonstrated that the frequency of activated FOXP3^+^ Tregs was reduced in individuals with type 1 diabetes when compared with control individuals without diabetes \[[@CR24]\].

In contrast to studies examining the frequency of Tregs, there is now a large body of evidence to suggest that FOXP3^+^ Treg function is altered in those with type 1 diabetes. In 2005, Lindley and colleagues reported for the first time that Tregs from individuals with type 1 diabetes were less able to control the proliferation of autologous Teffs than Tregs from HLA- and age-matched control individuals \[[@CR14]\], a finding since confirmed by many other researchers \[[@CR15], [@CR25]--[@CR28]\]. Furthermore, not only was suppression of proliferation altered in these co-cultures, but also the balance of cytokines produced was seen to differ: cells from individuals with diabetes produced predominantly proinflammatory cytokines, whereas the co-cultures from individuals without diabetes were dominated by anti-inflammatory cytokines, such as IL-10. Importantly, this reduced suppression is not only present close to diagnosis but is also present in individuals who have had type 1 diabetes for over 20 years. Reduced suppression thus appears to be consistent in type 1 diabetes over time, suggesting that the functional defect represents a stable phenotype. While decreased FOXP3^+^ Treg suppression has been observed independently by several groups, important questions remain regarding the cause, timing and relevance of these findings.

What causes reduced FOXP3^+^ Treg-mediated suppression? {#FPar2}
-------------------------------------------------------

The reduction in suppression observed in the studies described above could result from changes in either responder or regulatory T cells that were present in the co-cultures. This is a key issue, since many immunotherapy trials are aimed at improving Treg function in those with type 1 diabetes and understanding the nature of the defect is critical for correcting it. This important question has been examined in case--control studies using crossover co-cultures, mixing Tregs and Teffs. These studies observed both effector cell resistance to regulation and reduced Treg suppressive function in type 1 diabetes, with the relative contribution of each phenotype to reduced regulation varying between individuals \[[@CR27], [@CR28]\].

In contrast, data from the NOD mouse model of autoimmune diabetes suggest that increasing resistance to Teff regulation with disease progression \[[@CR29]\] is the primary cause for reduced suppression. However, there are key differences between type 1 diabetes and the preclinical model. For example, although it has been suggested that a relative deficiency in the strength of IL-2 signalling received by FOXP3^+^ Tregs in both mice and humans may play a key role in their functional deficiency (as discussed below in more detail), in mice this may be mainly driven by polymorphisms in *IL2*, resulting in reduced IL-2 production by Teffs \[[@CR30]\], while in humans, in addition to the type 1 diabetes-associated polymorphisms in *IL2*, other disease-associated polymorphisms that confer higher risk are also present in key elements of the IL-2 receptor (*IL2RA* and *IL2RB*) and molecules/phosphatases modulating downstream signalling of IL-2 (e.g. *PTPN2*) \[[@CR12], [@CR31], [@CR32]\]. In humans, therefore, the genes that are most relevant to Teff regulation exert their greatest effect in cells reliant upon IL-2 signalling for function and survival, such as Tregs. Thus, in human type 1 diabetes, 'resistance to regulation' may also be explained by the inability of Teffs to provide an environment conducive to Treg fitness and function, further compounded by intrinsic Treg defects.

In support of these concepts, in individuals with type 1 diabetes a wide variety of intrinsic differences within the Treg population has been reported, most of which could be viewed as representing less-fit or less-stable FOXP3^+^ Tregs (see Table [1](#Tab1){ref-type="table"} for details). Alterations in the Treg population in type 1 diabetes include increased levels of Treg apoptosis \[[@CR25], [@CR26]\], a decrease in the stability of FOXP3 expression \[[@CR33], [@CR34]\] and an increase in the frequency of Tregs that produce proinflammatory cytokines, such as IFN-γ and IL-17 \[[@CR35], [@CR36]\]. More recently, in an elegant study, Pesenacker and colleagues examined the expression of a panel of FOXP3^+^ Treg-specific transcripts in Tregs freshly isolated from individuals with recent-onset type 1 diabetes and well-matched individuals without diabetes \[[@CR37]\]. They identified a panel of six genes, including *FOXP3*, *TNFRSF1B* (*CD120b*) and *LRRC32* (*GARP*), which were directly linked to Treg function and stability and were differentially expressed in Tregs from individuals with diabetes. Similarly, other studies have identified subtle differences in gene expression profiles in Tregs according to type 1 diabetes presence or absence \[[@CR38]\].Table 1Intrinsic differences within the Treg population in type 1 diabetesTreg immunophenotype observedStudy authors (date)Individuals studiedStudy outcomesReduced Treg IL-2 sensitivityLong et al (2011) \[[@CR32]\]NDB, stratified by *PTPN22* genotypeThe T1D-associated genotype was associated with reduced IL-2 signallingGarg et al (2012) \[[@CR34]\]NDB stratified by *IL2RA* genotypeThe T1D-associated genotype was associated with reduced IL-2 signallingYang et al (2015) \[[@CR39]\]With long-standing T1DReduced IL-2 signalling was associated with the T1D-associated *PTPN2* genotype and lower levels of Treg-mediated suppressionCerosaletti et al (2013) \[[@CR95]\]With T1D; NDB but at riskReduced IL-2 signalling was observed in T1D vs NDB; IL-2 signalling was reduced in NDB with T1D-associated *PTPN2* and *IL2RA* genotypesLong et al (2010) \[[@CR33]\]With T1D; NDBReduced IL-2 signalling was observed in T1D vs NDBUnstable FOXP3 expressionLong et al (2010) \[[@CR33]\]With T1D; NDBReduced FOXP3 expression under conditions of limiting IL-2 in individuals with T1D vs NDBGarg et al (2012) \[[@CR34]\]NDB stratified by *IL2RA* genotypeThe T1D-associated genotype was associated with reduced FOXP3 expression under conditions of limiting IL-2Increased Treg apoptosisGlisic-Milosavljevic et al (2007) \[[@CR26]\]With recent-onset and long-standing T1D; islet AAb^+^ (at-risk); NDBIncreased Treg apoptosis was observed in recent-onset T1D and at-risk individuals with two or three AAbs when compared to low risk individuals and NDBGlisic-Milosavljevic et al (2007) \[[@CR25]\]With new-onset T1D; NDBLongitudinal study showing increased levels of Treg apoptosis close to diagnosis of T1D vs NDB, but this diminished over timeGlisic et al (2009) \[[@CR41], [@CR96]\]With recent-onset T1D; with long-standing T1D; NDBIncreased levels of Treg apoptosis was observed in recent-onset T1D vs NDB and associated with the high-risk *HLA*-*DQB1* haplotypeIncreased Treg proinflammatory cytokine secretionMcClymont et al (2011) \[[@CR35]\]With established T1D; NDBIncreased frequency of IFN-γ-producing Tregs in individuals with T1D vs NDB; these Tregs displayed reduced suppressive function compared with non-IFN-γ-producing TregsMarwaha et al (2010) \[[@CR36]\]With recent-onset T1D; NDBIncreased frequency of IL-17-producing cells in CD45RA^−^CD25^int^FOXP3^low^ T cells vs NDB, which displayed reduced suppressive functionAltered Treg transcriptomePesenacker et al (2016) \[[@CR37]\]With recent-onset T1D; with established T1D; NDBIdentified a panel of genes that are differentially expressed in Tregs from children with recent-onset T1D vs NDBFerraro et al (2014) \[[@CR38]\]With established T1D, with T2D; NDBA number of genes were shown to have reduced expression in individuals with T1D vs those withoutAAb, autoantibody; NDB, not diabetic; T1D, type 1 diabetes; T2D, type 2 diabetes

Given the key role that IL-2 signalling plays in maintaining FOXP3 expression, thereby maintaining Treg fitness, it has been postulated that many of the Treg-intrinsic defects observed in type 1 diabetes may be caused by a relative reduction in IL-2 signalling. Indeed, transcriptional profiles of Tregs from individuals with recent-onset diabetes share many features with IL-2-starved, apoptosis-prone Tregs. Yang and colleagues recently linked many of these associations together for the first time, demonstrating that individuals with type 1 diabetes and low IL-2 signalling had Tregs that were less able to maintain FOXP3 expression under limiting concentrations of IL-2 and displayed reduced suppressor function \[[@CR39]\]. Although our knowledge of factors that influence FOXP3^+^ Treg stability and function has increased rapidly over the past few years, and the possibility that differential IL-2 signalling may explain at least some of the differences seen in those with type 1 diabetes, a full understanding of the precise molecular basis underlying FOXP3^+^ Treg dysfunction in type 1 diabetes is still lacking and warrants further investigation. In summary, the fitness and function of Tregs and Teffs may be inextricably linked. However, phenotypic differences are clearly observable in Tregs when comparing those from individuals with and without type 1 diabetes, irrespective of whether this is primarily a case of 'nature' or 'nurture'.

Is reduced FOXP3^+^ Treg function a cause or effect of disease? {#FPar3}
---------------------------------------------------------------

To better understand how tolerance is lost in type 1 diabetes, a key issue to address is whether the decreased suppressive capability of Tregs is due to changes in the immune system that are caused by development of type 1 diabetes or whether Treg dysfunction is involved in disease initiation. Studies examining Treg function in individuals with stage 1 diabetes, as defined by autoantibody positivity, suggest that Treg defects pre-date clinical disease, supporting a causative role for Treg dysfunction \[[@CR26], [@CR40]\]. However, interpretation of these results is not straightforward because although these individuals do not show overt diabetes, they may already have islet inflammation which could influence Treg function. An alternative approach is to assess Treg fitness and function in individuals who possess a high-risk haplotype for type 1 diabetes but who have no evidence of disease. These genotype--phenotype studies rest on the hypothesis that if a type 1 diabetes susceptibility genotype is associated with altered Treg function, then Treg dysfunction is likely to be causal in type 1 diabetes. To date, such studies have demonstrated that polymorphisms in *IL2RA* and *PTPN2* are indeed associated with reduced Treg fitness and/or function in the absence of disease \[[@CR32], [@CR34]\]. These observations in individuals without diabetes are supported by similar genotype--phenotype studies in individuals with type 1 diabetes, including the associations between Treg IL-2 sensitivity and *IL2RA* genotype \[[@CR39]\] and between Treg apoptosis and HLA class II haplotype \[[@CR41]\]. While these studies all support a causative role for Treg dysfunction in type 1 diabetes, to fully understand the timing of Treg dysfunction and its relationship with disease progression, longitudinal studies are required that follow individuals at high risk through the stages of type 1 diabetes. Such studies may lead to the correlation of Treg function with the breakdown of immunological tolerance, the emergence of activated autoreactive T cells and the progression to beta cell destruction.

Where does the imbalance in FOXP3^+^ Treg function occur? {#FPar4}
---------------------------------------------------------

The studies discussed so far demonstrate reduced FOXP3^+^ Treg function in type 1 diabetes, but an important caveat is that their conclusions are drawn based on a phenotype found in circulating peripheral Tregs rather than Tregs present at the site of tissue damage. Studies in the NOD mouse have highlighted the fact that Treg dysfunction is mainly limited to the pancreas and draining lymph nodes. In this model of type 1 diabetes, as the disease develops the frequency of Tregs increases in the pancreatic draining lymph node (PLN) but decreases in the pancreas, with reduced Treg CD25 expression and an increase in apoptosis being observed. Successful treatment of NOD mice by IL-2 therapy, leading to reversal of disease, specifically prevents the loss of Tregs in the pancreas \[[@CR11]\], demonstrating the importance of studying Tregs from the site of tissue damage.

Although such studies are not easily performed in human type 1 diabetes, relevant observations have been made using tissue recovered from donor cadavers. Interestingly, these studies have revealed important differences between mouse and human insulitis. Most notably, infiltration in human islets is far less florid than seen in mouse islets and rarely contains any FOXP3^+^ Tregs, suggesting that regulation of the immune response takes place at another location \[[@CR42]\]. In this regard, an important study by Ferraro and colleagues revealed differences in Tregs from the PLN of individuals with type 1 diabetes \[[@CR43]\]. These investigators observed decreased levels of suppression by Tregs obtained from the PLN of individuals with type 1 diabetes and an increase in secretion of the proinflammatory cytokine IL-17. These studies demonstrate the importance of tissue-specific investigations and suggest that the PLN may be a key site of Treg dysfunction in type 1 diabetes. Furthermore, detailed studies using cells isolated from a variety of anatomical sites, such as those available via the JDRF-sponsored Network for Pancreatic Organ donors with Diabetes programme (nPOD), will be vital for gaining a deeper insight into immune dysregulation in type 1 diabetes closer to the target organ.

Is reduced FOXP3^+^ Treg function universal in type 1 diabetes? {#FPar5}
---------------------------------------------------------------

Another topic worthy of discussion is the degree of heterogeneity of Treg function observed in all studies to date. From the studies described above, one could conclude that reduced Treg function plays a role in all type 1 diabetes development. However, it is worth noting that, to date, all studies examining FOXP3^+^ Treg function have found a large degree of overlap between individuals with and without type 1 diabetes, with only a subgroup of individuals with type 1 diabetes clearly displaying the immune phenotype associated with poor function. This suggests that the reduced Treg function observed using these assays may be restricted to, or more easily revealed in, a subset of individuals with type 1 diabetes. Understanding how to stratify individuals in terms of the specific defects that have led to an imbalanced immune response will be critical when deciding who is likely to benefit from a given immunotherapy. An example highlighting the heterogeneity seen within type 1 diabetes cohorts demonstrated variation in the IL-2 sensitivity of Tregs from different individuals \[[@CR44]\]. Those with reduced Treg IL-2 sensitivity had unstable FOXP3 expression and poor suppressor capabilities and it is possible that these individuals would benefit from IL-2 immunotherapy. As we continue to develop our understanding of the heterogeneity present within individuals with type 1 diabetes, it is important to test potential therapies in those who are most likely to benefit from a given treatment, highlighting the need for a personalised approach to immunotherapy in type 1 diabetes.

CD4^+^FOXP3^−^ Treg cells {#Sec3}
=========================

In addition to FOXP3^+^ Tregs, other subsets of CD4 T cells with regulatory properties have been described, including one characterised by secretion of high levels of IL-10 upon recognition of cognate peptide. Often referred to as T regulatory type 1 (Tr1) Tregs, these cells were first described in individuals who developed tolerance following HLA-mismatched haematopoietic stem-cell transplantation \[[@CR45]\]. Tr1 cells are capable of suppressing T cell responses and modulating antigen-presenting cell (APC) function via a variety of mechanisms, including expression of inhibitory cell surface receptors, cytolytic activity and secretion of soluble factors \[[@CR46]\]. The mechanism by which Tr1 cells are naturally induced in vivo remains poorly understood, although evidence from mouse models and human studies suggests that they are generated from naive CD4 T cells upon repeated stimulation with self or foreign antigens presented by immature or tolerogenic dendritic cells. Numerous experimental models have demonstrated that Tr1 cells play a key role in maintaining tolerance to both self-antigens and gut microbiota \[[@CR46]\]. Furthermore, defects in the number and/or functional potential of Tr1 (or Tr1-like) cells have been implicated in the pathogenesis of a range of human autoimmune \[[@CR47]--[@CR49]\] and allergic conditions \[[@CR50]\].

Islet-specific IL-10-secreting cells in type 1 diabetes {#FPar6}
-------------------------------------------------------

A mounting body of evidence now suggests that islet-specific Tr1-like cells may play an important role in the development of type 1 diabetes. In 2004 Arif and colleagues identified a novel population of naturally arising CD4^+^ T cells that secrete IL-10 following exposure to islet autoantigens \[[@CR51]\]. Subsequent isolation and functional characterisation of these naturally occurring islet-specific T cells from individuals without diabetes demonstrated that they share many properties with Tr1 cells and exert a potent regulatory function. In vitro, this regulatory function is primarily mediated by the specific destruction of APCs presenting islet peptides. This mechanism prevents activation of proinflammatory T cells by the same APC and, if operational in vivo, would represent a potentially important mechanism of maintaining antigen-specific tolerance. Studies investigating the frequency of these cells in individuals with varying backgrounds of islet autoimmunity have made several important observations. First, these cells are enriched in those at risk of type 1 diabetes but with no evidence of pathogenic islet autoimmunity, such as individuals without diabetes but carrying high-risk HLA class II molecules \[[@CR51]\]. Second, IL-10-secreting Tregs that are observed in those with type 1 diabetes are associated with less-aggressive autoimmunity as demonstrated by a reduced magnitude of proinflammatory islet-specific T cells and fewer autoantibodies \[[@CR52]\], a later age of onset \[[@CR51]\] and superior glycaemic control after diagnosis \[[@CR53]\]. Third, although the overall frequency of islet-specific IL-10-secreting T cells does not differ between those with type 1 diabetes and autoantibody-negative first-degree relatives (FDRs), cells from FDRs were observed to secrete more IL-10, suggesting potential functional differences in these cells; this warrants further investigation \[[@CR54]\]. Taken together, these data suggest that islet-specific IL-10-secreting cells are associated with protection from pathological islet autoimmunity and offer a potentially powerful method by which to strengthen tolerance in an antigen-specific manner.

Promoting immune regulation in type 1 diabetes {#Sec4}
==============================================

Despite heterogeneity within type 1 diabetes cohorts, promoting immune regulation, even in individuals who do not have reduced Treg frequency or function, may tip the balance of the immune response enough to promote protection of beta cells. Evidence is mounting from clinical studies in type 1 diabetes and other conditions characterised by immune dysregulation that such therapeutic approaches might have an impact upon established and developing disease (see Fig. [1](#Fig1){ref-type="fig"} for a summary of Treg defects and current immunotherapies aimed at strengthening immune regulation).Fig. 1Alterations in Treg phenotype and function observed in type 1 diabetes. FOXP3^+^ Tregs from individuals with type 1 diabetes are less able to control the proliferation of and cytokine production by effector CD4^+^ T cells compared with those from individuals without diabetes. This defective regulation may be owing to two non-mutually exclusive factors: differences in the Teff population (shown in red boxes) and/or Treg intrinsic defects (shown in blue boxes) (where differences overlap, details are shown in red/blue boxes). Additionally, the frequency and function of induced Tregs (iTregs) may play a role in promoting imbalance of the immune system in type 1 diabetes (green boxes). In many cases, these immunophenotypes may be influenced by gene polymorphisms associated with type 1 diabetes susceptibility (shown in grey boxes). Potential avenues for strengthening immune regulation by Treg invigoration are indicated in beige boxes. Red circles, IFN-γ/IL-17; green circles, IL-10. The grey arrow represents how unstable expression profiles of FOXP3 by Tregs increases the production of proinflammatory cytokines, promoting the function and expansion of islet-destructive Teff cells. MHC-CII, *HLA-DRB1*/*HLA-DQA1*/*HLA-DQB1*; STAT, signal transducer and activator of transcription; Th, T helper

Agents that alter the balance of effector:regulatory T cells {#FPar7}
------------------------------------------------------------

Several monoclonal antibodies and small-molecule therapies that were initially developed to treat other diseases have been found to demonstrate clinical benefit in type 1 diabetes and may operate by altering Treg frequency or function. Treatment of individuals with type 1 diabetes with alefacept (a lymphocyte function-associated antigen-3 immunoglobulin \[LFA-3Ig\] fusion protein that binds to CD2 and depletes T cells displaying high levels of this surface antigen) significantly decreased dependency on exogenous insulin 24 months after treatment \[[@CR55]\]. This effect correlated with an increase in the ratio of FOXP3^+^ Tregs to CD4^+^ and CD8^+^ effector and central memory T cells. In another study, combination therapy with antithymocyte globulin and granulocyte colony stimulating factor increased or preserved beta cell function in individuals with type 1 diabetes when measured 1 year following treatment \[[@CR56]\] and this was associated with a higher frequency of FOXP3^+^ Tregs. Taken together, these studies support further investigation of the therapeutic potential of Tregs in type 1 diabetes.

Monoclonal antibody therapies blocking proinflammatory cytokines may also represent a method by which Treg function can be promoted. It is well known that Treg-mediated suppression can be reduced in the presence of pro-inflammatory cytokines, such as IL-6. The potential of anti-IL-6 therapy has previously been demonstrated in a variety of conditions, including systemic lupus erythematosus and Crohn's disease (reviewed by Nepom et al \[[@CR57]\]) and a clinical trial testing anti-IL6 therapy in type 1 diabetes has begun ([ClinicalTrials.gov](http://clinicaltrials.gov) registration no. NCT02293837) \[[@CR58]\].

Direct targeting of FOXP3^+^ Tregs by IL-2 administration {#FPar8}
---------------------------------------------------------

Clinical trials have now begun testing therapies that are specifically designed to promote the expansion or function of FOXP3^+^ Tregs in type 1 diabetes. One such strategy, supported by observations on Treg dysfunction, is to use exogenously administered low-dose IL-2 to selectively promote Treg function with the rationale that Tregs respond to lower doses of IL-2 compared with other cells of the immune system because of their high expression levels of CD25 \[[@CR59]\]. Similar studies in other conditions marked by immune dysregulation, including chronic graft-versus-host disease (GvHD) \[[@CR60], [@CR61]\], hepatitis C virus-induced vasculitis \[[@CR62]\], systemic lupus erythematosus \[[@CR63]\] and alopecia areata \[[@CR64]\], have been conducted with encouraging results. A Phase I/II clinical trial in type 1 diabetes \[[@CR65]\] demonstrated the safety of low-dose IL-2 administration and an increase in the frequency of pTregs was observed. Similar studies in other conditions marked by immune dysregulation have shown great promise and clinical benefit in some individuals. A second clinical trial, conducted by Diabetes TrialNet and the Immune Tolerance Network, used higher doses of IL-2 in combination with the inhibitor of the mammalian target of rapamycin (mTOR), rapamycin. While this therapy led to an increase in Treg frequency, it also induced a transient reduction in beta cell function, possibly owing to off-target effects on other cell populations such as natural killer (NK) cells \[[@CR66], [@CR67]\]. This study clearly highlights the importance of carefully assessing the dose and frequency of IL-2 administration to selectively target Tregs while avoiding unwanted off-target effects. These issues are being investigated intensively in mechanistic studies with immunological endpoints prior to conducting fully powered Phase II efficacy trials \[[@CR68], [@CR69]\].

Adoptive Treg cell therapy {#FPar9}
--------------------------

An alternative method to promote immune regulation by Tregs is to increase their frequency by adoptively transferring autologous Treg populations. Recent advances in cell sorting allow for the isolation of highly pure FOXP3^+^ Tregs, under conditions of good manufacturing practice, using a cell surface phenotype of CD4^+^CD25^high^CD127^low^. Subsequent polyclonal stimulation of isolated FOXP3^+^ Tregs ex vivo leads to the expansion of billions of cells from a single blood draw, allowing for their therapeutic potential to be explored. The first clinical trial applying adoptive polyclonal Treg therapy to type 1 diabetes was completed in 2012 \[[@CR70]\]. Administration of autologous, expanded CD4^+^CD25^high^CD127^low^ Tregs to children within 2 months of type 1 diabetes diagnosis significantly increased pTreg frequency, coinciding with a decrease in dependency on exogenous insulin. A 1 year follow-up study showed that 8 out of 12 children treated with Tregs required less exogenous insulin and two children were independent of exogenous insulin \[[@CR71]\]. A second Phase I safety trial in individuals diagnosed with type 1 diabetes within 2 years of recruitment was also completed in 2015, further demonstrating the safety and feasibility of this approach \[[@CR72]\].

While the initial clinical trials using polyclonal Treg therapy in type 1 diabetes demonstrate the feasibility and safety of this approach, studies in the NOD mouse suggest that islet antigen-specific Tregs would be more efficacious as a therapy \[[@CR73]--[@CR75]\]. Large populations of murine antigen-specific Tregs can be produced with ease using T cell receptor (TCR)-transgenic mice, but in humans this is difficult as islet antigen-specific Tregs within the pTreg pool are very rare. Selective expansion of antigen-specific Tregs has been used to produce alloantigen-specific populations to treat GvHD. Tregs specific for alloantigens presented by donor-derived B cells stimulated with CD40 ligand were successfully expanded to clinically relevant numbers \[[@CR76]\]. This approach is unlikely to be successful in type 1 diabetes as there are fewer antigens involved in the autoimmune response and, therefore, Tregs with a relevant specificity have an even lower frequency. Expansion of all islet antigen-specific CD4^+^ T cells could also be a strategy, since stimulation of Teffs via their TCR has been found to induce a subpopulation of cells with regulatory potential \[[@CR77]\] and the presence of TGF-β in cultures has also been shown to induce Treg populations \[[@CR78]\]. Using culture conditions to skew T cells towards a regulatory phenotype has the disadvantage that once cells are adoptively transferred, the stability of their regulatory phenotype is unknown. One option to improve the stability of Treg populations is by ectopic expression of FOXP3 to achieve a homogeneous FOXP3^+^ Treg population with potent regulatory potential \[[@CR79], [@CR80]\]. An alternative that has received a great deal of attention in both autoimmunity and cancer therapy is the redirection of T cell specificity using TCR gene therapy. In type 1 diabetes, the antigen specificity of polyclonal Treg populations could be redirected towards islet antigens to produce large populations of islet antigen-specific Tregs. A proof of principle study has indeed demonstrated that human Treg antigen specificity can be redirected by TCR gene transfer \[[@CR81]\].

Further development of adoptive Treg therapy may need to consider the homing potential of Treg populations in addition to their antigen specificities. It has previously been demonstrated in the NOD mouse that adoptive transfer of CD62L^+^ but not CD62L^−^ Tregs inhibited type 1 diabetes development. In humans, isolation of CD45RA^+^ rather than CD45RA^−^ Tregs produced a homogeneous population of Tregs that expressed lymph node homing receptors, including CCR7 and CD62L \[[@CR22], [@CR82]\]. The use of drugs, such as rapamycin and all-trans retinoic acid (ATRA), influences the homing signatures of human Treg populations produced for adoptive cell therapy. Tregs expanded in the presence of rapamycin express skin homing receptors, such as CCR4, while those expanded in the presence of ATRA express gut homing receptors, such as α4β7 integrin \[[@CR83]\]. Expansion using a combination of both drugs produces a Treg population with a diverse range of homing receptors. Together, these data provide an insight into how isolation and expansion methods can be used to 'imprint' different homing profiles on Treg populations, adding an additional level of control. The use of adoptive Treg therapy in type 1 diabetes may be in its infancy but recent advances in the fields of cancer and transplantation demonstrate that adoptive cell therapies may hold great promise for rebalancing the human immune system.

Expanding islet-specific Tregs by antigen-specific immunotherapy {#FPar10}
----------------------------------------------------------------

It has long been acknowledged that administration of antigens or peptides under tolerogenic conditions has the potential to induce or expand populations of antigen-specific Tregs capable of modulating disease. In animal models of type 1 diabetes, administration of islet autoantigen using a variety of tolerogenic regimens has provided protection against islet destruction, which is often associated with an increase in IL-10 production by CD4^+^ T cells, although in many cases the regulatory potential of these cells is not well understood \[[@CR84]--[@CR86]\]. More recently, in a humanised HLA-transgenic mouse model of islet autoimmunity, Gibson and colleagues demonstrated that, while peptide presented by tolerogenic dendritic cells controlled autoimmunity and was associated with islet-specific IL-10 production, intradermal injection of the same peptide also reduced autoimmunity and increased the proliferation of FOXP3^+^ Tregs \[[@CR87]\]. This elegantly demonstrates that the route and method of delivery of an antigen-specific immunotherapy can influence the mechanism by which it may afford protection. In human type 1 diabetes, administration of the islet autoantigen GAD65 in alum resulted in some preservation of islet function in new-onset type 1 diabetes in Phase II trials \[[@CR88]\] but failed to meet its primary endpoints in Phase III trials \[[@CR89]\]. Treatment was associated with increased expression of FOXP3 in T cells stimulated with GAD65 ex vivo, although this response was not associated with preserved C-peptide and it was unclear whether it reflected an increase in bona fide FOXP3^+^ Tregs or activated Teffs \[[@CR90]\]. In a 2009 Phase I study in individuals with type 1 diabetes, those who were given low doses of proinsulin peptide showed an increase in peptide-specific IL-10 responses when compared with individuals given placebo, demonstrating proof of concept \[[@CR91]\]. Other trials using islet peptides representing known epitopes recognised by CD4^+^ T cells are ongoing. Several of these involve novel methods of delivery aimed at increasing the potential to induce Treg responses, including loading peptide onto tolerogenic dendritic cells \[[@CR92]\] or conjugating the peptides to nanoparticles \[[@CR93]\], and appear to induce populations of Tregs with similar properties to the naturally occurring IL-10-secreting cells described above \[[@CR94], [@CR95]\].

Compared with the progress in other fields (such as allergy), antigen-specific immunotherapy in type 1 diabetes may still be in its infancy. However, it remains a potentially powerful weapon that has the potential to specifically control islet autoimmunity, thereby avoiding many of the potential adverse events that may be associated with more generalised immunosuppression.

Conclusions {#Sec5}
===========

Partly fuelled by observations of diminished Treg function or frequency in type 1 diabetes, the strengthening of immunoregulation by Treg invigoration is a major area of clinical trial activity. However, despite the focus of several high-profile clinical studies on increasing Tregs via therapeutic intervention, key questions remain unanswered: when and precisely how do changes in Treg populations arise? How can we best identify individuals with dysfunctional Tregs? Who will benefit from particular forms of immunotherapy? What are the best ways to increase Treg frequency or function? Gaining a better understanding of the natural history of Treg function in type 1 diabetes and unravelling the molecular profile of functional and dysfunctional Treg subsets has the potential to increase our understanding of the molecular basis of type 1 diabetes and may reveal new targets for immunotherapy. These studies may also identify biomarkers that can be deployed in ongoing clinical trials and ultimately offer the potential to stratify individuals who may benefit most from Treg-strengthening therapies.
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APC

:   Antigen-presenting cell

ATRA

:   All-trans retinoic acid

FDR

:   First-degree relative

FOXP3

:   Forkhead box P3

GvHD

:   Graft-versus-host disease

IPEX

:   Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome

PLN

:   Pancreatic draining lymph node

pTreg

:   Regulatory T cell generated in the periphery

TCR

:   T cell receptor

Teff

:   Effector T cell

Tr1

:   T regulatory type 1

Treg

:   Regulatory T cell

tTreg

:   Regulatory T cell generated in the thymus
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